DOCSLIB.ORG

1111111111111111111Imnumu

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

1111111111111111111imnumu (12) United States Patent (1o) Patent No.: US 9,005,185 B2 Ferrari et al. (45) Date of Patent: Apr. 14, 2015 (54) NANOCHANNELED DEVICE AND RELATED (52) U.S. Cl. METHODS CPC .............. A61M37/00(2013.01);A61K910097 (2013.01); B81C1100119 (2013.01); B82Y5100 (71) Applicants: The Board of Regents of the University (2013.01); A61M 5114276 (2013.01); B81B of Texas System, Austin, TX (US); The 22011058 (2013.01); B81B 220310338 Ohio State University Research (2013.01) Foundation, Columbus, OH (US) (58) Field of Classification Search CPC . A61M 5/14276; A61M 5/141; A61M 37/00; (72) Inventors: Mauro Ferrari, Houston, TX (US); A61 M 2209/045; A61 M 2039/0264; A61 M 2039/0291; A61F 2250/0068; A61K 9/0097; Xuewu Liu, Sugar Land, TX (US); 138113 2201/058; 138113 2203/0338 Alessandro Grattoni, Houston, TX USPC ........ 604/246, 288.01, 288.02, 288.04, 891.1 (US); Randy Goodall, Austin, TX (US); See application file for complete search history. Lee Hudson, Elgin, TX (US) (56) References Cited (73) Assignees: The Board of Regents of the University of Texas System, Austin, TX (US); The U.S. PATENT DOCUMENTS Ohio State University Research Foundation, Columbus, OH (US) 3,731,681 A 5/1973 Blackshear et al. 3,921,636 A 11/1975 Zaffaroni (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days. FOREIGN PATENT DOCUMENTS (21) Appl. No.: 14/099,429 DE 10 2006 014476 7/2007 EP 1 977 775 10/2008 (22) Filed: Dec. 6, 2013 (Continued) (65) Prior Publication Data OTHER PUBLICATIONS US 2014/0180251 Al Jun. 26, 2014 "The Economic Costs of Drug Abuse in the United States," www. whitehousedrugpolicy.gov, Sep. 2001. (Continued) Related U.S. Application Data (63) Continuation of application No. 13/264,069, filed as Primary Examiner Nicholas Lucchesi application No. PCT/US2010/030937 on Apr. 13, Assistant Examiner Gerald Landry, II 2010, now Pat. No. 8,632,510, which is a (74) Attorney, Agent, or Firm Parker Highlander PLLC (Continued) (57) ABSTRACT (51) Int. Cl. A capsule configured for in vivo refilling of a therapeutic A61K9122 (2006.01) agent. In certain embodiments, the capsule may contain A61M37100 (2006.01) methotrexate. (Continued) 14 Claims, 39 Drawing Sheets 636 1624 11 .- 1634 1616 11 , 1 626 1650 1614 1613 1 '1 1602 1600 US 9,005,185 B2 Page 2 Related U.S. Application Data OTHER PUBLICATIONS "Under the Counter: The Diversion and Abuse of Controlled Pre- continuation-in-part of application No. 12/618,233, scription Drugs in the US," The National Center on Addiction and filed on Nov. 13, 2009, now Pat. No. 8,480,637. Substance Abuse (CASA) at Columbia University, New York, NY, (60) Provisional application No. 61/168,844, filed on Apr. CASA, Jul. 2005. 13, 2009, provisional application No. 61/114,687, Christensen et al., "Tantalum oxide thin films as protective coatings filed on Nov. 14, 2008. for sensors," J. Micromech. Microeng., 9:113-118, 1999. Extended European Search Report issued in European Application (51) Int. Cl. No. 10765046, mailed Oct. 1, 2012. A61K9/00 (2006.01) Extended European Search Report issued in European Application B81C1/00 (2006.01) No. 09826831, mailed Jul. 12, 2012. B82Y5100 (2011.01) Fine et al., "A robust nanofiuidic membrane with tunable zero-order release for implantable dose specific drug delivery," Lab on a Chip, A61M51142 (2006.01) 10(2): 3074-3083, 2010. Hammerle et al., `Biostability of micro-photodiode arrays for (56) References Cited subretinal implantation," Biomaterials., 23:797-804, 2002. U.S. PATENT DOCUMENTS Hess et al., "PECVD silicon carbide as athin filmpackaging material for microfabricated neural electrodes," Mater. Res. Soc. Symp. Proc., 4,834,704 A 5/1989 Reinicke 1009-U04-03, 2007. 4,955,861 A 9/1990 Enegren et al. Narayan et al., "Mechanical and biological properties of nanoporous 5,085,656 A * 2/1992 Polaschegg ............. 604/891.1 carbon membranes," Biomed. Mater., 3:034107, 2008. 5,395,324 A 3/1995 Hinrichs et al. Nath et al., `Buprenorphine pharmacokinetics: relative bioavail- 5,651,900 A 7/1997 Keller et al. ability of sublingual tablet and liquid formulations," J Clin. 5,728,396 A 3/1998 Peery et al. 5,769,823 A 6/1998 Otto Pharmacol., 39:619-623, 1999. 5,770,076 A 6/1998 Chu et al. Nurdin et al., "Haemocompatibility evaluation of DLC-and SIC- 5,798,042 A 8/1998 Chu et al. coated surfaces," Ear Cells Mat., 5: 17-28, 2003. 5,893,974 A 4/1999 Keller et al. Office Action issued in European Application No. 09826831, mailed 5,938,923 A 8/1999 Tu et al. Jul. 11, 2013. 5,948,255 A 9/1999 Keller et al. Office Action issued in European Application No. 10765046, mailed 5,985,164 A 11/1999 Chu etal. Jul. 11, 2013. 5,985,328 A 11/1999 Chu et al. 6,044,981 A 4/2000 Chu et al. Office Action issued in U.S. Appl. No. 12/618,233, mailed Oct. 16, 6,592,519 B1 7/2003 Martinez 2012. 7,025,871 132 4/2006 Broadley et al. Office Action issued in U.S. Appl. No. 13/264,069, mailed Feb. 22, 7,135,144 132 11/2006 Christel et al. 2013. 7,326,561 132 * 2/2008 Goodman et al. ...... 435/286.5 Office Action issued in U.S. Appl. No. 13/264,069, mailed Oct. 29, 7,955,614 132 6/2011 Martin et al. 2012. 2002/0087120 Al 7/2002 Rogers et al. 2002/0156462 Al 10/2002 Stultz PCT International Search Report and Written Opinion issued in 2003/0010638 Al 1/2003 Hansford et al. International Application No. PCT/US2011/037094, dated Jan. 13, 2003/0064095 Al 4/2003 Martin et al. 2012. 2 004/003 82 60 Al 2/2004 Martin et al. PCT International Search Report and Written Opinion issued in 2004/0082908 Al 4/2004 Whitehurst et al. International Application No. PCT/US2010/030937, dated Feb. 21, 2004/0116905 Al 6/2004 Pedersen et al. 2011. 2004/0260418 Al * 12/2004 Staats ..................... 700/97 PCT International Search Report and Written Opinion issued in 2004/0262159 Al 12/2004 Martin et al. 2005/0118229 Al 6/2005 Boiarski International Application No. PCT/US2009/064376, mailedAug.23, 2006/0180469 Al* 8/2006 Han et al ................. 204/601 2010. 2006/0191831 Al 8/2006 Hansford et al. Report: Stakeholder Workshop on a National Buprenorphine Pro- 2006/0259015 Al * 11/2006 Steinbach ............... 604/891.1 gram, Health Canada, Nov. 18, 2004. 2006/0270983 Al* 11/2006 Lord et al . .............. 604/131 Samhsa, "Overview of Findings from the 2002 National Survey on 2007/0066138 Al 3/2007 Ferrari et al. Drug Use and Health," Rockville, MD, DHHS publication, SMA 2007/0077273 Al* 4/2007 Martin et al. ........... 424/423 03-3774. 2007/0286773 Al* 12/2007 Schlautmann et al. 422/68.1 2008/0073506 Al 3/2008 Lazar Samhsa, "Results from the 2003 National Survey on Drug Use and 2 009/02 143 92 Al 8/2009 Kameoka et al. Health: National Findings," Rockeville, MD, DHHS publication, 2010/0152699 Al 6/2010 Ferrari et al. SMA 04-3964. 2011/0137596 Al 6/2011 Grattoni et al. Samhsa, "The Dawn Report: oxycodaone, hydrocodone, and polydrug use," 2002. Jul. 2004 http://oas.samhsa.gov/2k4/ FOREIGN PATENT DOCUMENTS oxycodone/oxycodone.cfm. Schmitt et al., "Passivation and corrosion of microelctrode arrays," WO WO 00/74751 12/2000 Electrochimica Acta, 44:3865-3883, 1999. WO WO 2004/036623 4/2004 Voskerician et al., `Biocompatibility and biofouling of MEMS drug WO WO 2005/079387 9/2005 delivery devices," Biomaterials, 24:1959-1967, 2003. WO WO 2006/113860 10/2006 Yakimova et al., "Surface functionalization and biomedical applica- WO WO 2007/047539 4/2007 tions base on SiC,"JPhysics D, 40: 6435- 6442, 2007. WO WO 2007/089483 8/2007 WO WO 2008/019886 9/2008 Zorman et al., "Silicon carbide as a material for biomedical WO WO 2009/149362 12/2009 Microsystems," DIT, Apr. 1-3, 2009. WO WO 2010/056986 5/2010 WO WO 2010/120817 10/2010 * cited by examiner U.S. Patent Apr. 14, 2015 Sheet 1 of 39 US 9,005,185 B2 *i M 3'`C~~ `✓ _ 7 i ;i Q V-ft ^ep~Paad C6: e °pia Nz F~ 11 1 l cm iz °ape 3 3j1> i U- 1 U.S. Patent Apr. 14 , 2015 Sheet 2 of 39 US 9,005,185 B2 10 15 FIG. 2A 10 --"~ 15 " P~ 25 F1.2 U.S. Patent Apr. 14, 2015 Sheet 3 of 39 US 9,005,185 B2 10 15 25 FIG. 2C 25 20 FIG. 2D U.S. Patent Apr. 14, 2015 Sheet 4 of 39 US 9,005,185 B2 25 20 FIG. 2E U.S. Patent Apr. 14, 2015 Sheet 5 of 39 US 9,005,185 B2 FIG. 3B FIG. 3C U.S. Patent Apr. 14, 2015 Sheet 6 of 39 US 9,005,185 B2 of 60 70 25 20 40 F1.3 U.S. Patent Apr. 14, 2015 Sheet 7 of 39 US 9,005,185 B2 20 *-40 FIG. 3E 20 FIG. 3F U.S. Patent Apr. 14, 2015 Sheet 8 of 39 US 9,005,185 B2 FIG. 3G U.S. Patent Apr. 14, 2015 Sheet 9 of 39 US 9,005,185 B2 3 cm a i - u r µ t' r CZ CI ! i`3t kti1 j~ I X } } . i f r cz a y s U.S.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective

    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
  • Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa Ursula F

    Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa Ursula F

    Exaggerated 5-HT1A but Normal 5-HT2A Receptor Activity in Individuals Ill with Anorexia Nervosa Ursula F. Bailer, Guido K. Frank, Shannan E. Henry, Julie C. Price, Carolyn C. Meltzer, Chester A. Mathis, Angela Wagner, Laura Thornton, Jessica Hoge, Scott K. Ziolko, Carl R. Becker, Claire W. McConaha, and Walter H. Kaye Background: Many studies have found disturbances of serotonin (5-HT) activity in anorexia nervosa (AN). Because little is known about 5-HT receptor function in AN, positron emission tomography (PET) imaging with 5-HT receptor-specific radioligands was used to character- ize 5-HT1A and 5-HT2A receptors. Methods: Fifteen women ill with AN (ILL AN) were compared with 29 healthy control women (CW); PET and [11C]WAY100635 were used to assess binding potential (BP) of the 5-HT1A receptor, and [18F]altanserin was used to assess postsynaptic 5-HT2A receptor BP. [15O] water and PET were used to assess cerebral blood flow. Results: The ILL AN women had a highly significant (30%–70%) increase in [11C]WAY100635 BP in prefrontal and lateral orbital frontal regions, mesial and lateral temporal lobes, parietal cortex, and dorsal raphe nuclei compared with CW. The [18F]altanserin BP was normal in ILL AN but was positively and significantly related to harm avoidance in suprapragenual cingulate, frontal, and parietal regions. Cerebral blood flow was normal in ILL AN women. Conclusions: Increased activity of 5-HT1A receptor activity may help explain poor response to 5-HT medication in ILL AN. This study extends data suggesting that 5-HT function, and, specifically, the 5-HT2A receptor, is related to anxiety in AN.
  • Customs Tariff - Schedule

    Customs Tariff - Schedule

    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017

    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
  • Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    Classification Decisions Taken by the Harmonized System Committee from the 47Th to 60Th Sessions (2011

    CLASSIFICATION DECISIONS TAKEN BY THE HARMONIZED SYSTEM COMMITTEE FROM THE 47TH TO 60TH SESSIONS (2011 - 2018) WORLD CUSTOMS ORGANIZATION Rue du Marché 30 B-1210 Brussels Belgium November 2011 Copyright © 2011 World Customs Organization. All rights reserved. Requests and inquiries concerning translation, reproduction and adaptation rights should be addressed to [email protected]. D/2011/0448/25 The following list contains the classification decisions (other than those subject to a reservation) taken by the Harmonized System Committee ( 47th Session – March 2011) on specific products, together with their related Harmonized System code numbers and, in certain cases, the classification rationale. Advice Parties seeking to import or export merchandise covered by a decision are advised to verify the implementation of the decision by the importing or exporting country, as the case may be. HS codes Classification No Product description Classification considered rationale 1. Preparation, in the form of a powder, consisting of 92 % sugar, 6 % 2106.90 GRIs 1 and 6 black currant powder, anticaking agent, citric acid and black currant flavouring, put up for retail sale in 32-gram sachets, intended to be consumed as a beverage after mixing with hot water. 2. Vanutide cridificar (INN List 100). 3002.20 3. Certain INN products. Chapters 28, 29 (See “INN List 101” at the end of this publication.) and 30 4. Certain INN products. Chapters 13, 29 (See “INN List 102” at the end of this publication.) and 30 5. Certain INN products. Chapters 28, 29, (See “INN List 103” at the end of this publication.) 30, 35 and 39 6. Re-classification of INN products.
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • Test–Retest Variability of Serotonin 5-HT2A Receptor Binding Measured with Positron Emission Tomography and [18F]Altanserin in the Human Brain

    Test–Retest Variability of Serotonin 5-HT2A Receptor Binding Measured with Positron Emission Tomography and [18F]Altanserin in the Human Brain

    SYNAPSE 30:380–392 (1998) Test–Retest Variability of Serotonin 5-HT2A Receptor Binding Measured With Positron Emission Tomography and [18F]Altanserin in the Human Brain GWENN S. SMITH,1,2* JULIE C. PRICE,2 BRIAN J. LOPRESTI,2 YIYUN HUANG,2 NORMAN SIMPSON,2 DANIEL HOLT,2 N. SCOTT MASON,2 CAROLYN CIDIS MELTZER,1,2 ROBERT A. SWEET,1 THOMAS NICHOLS,2 DONALD SASHIN,2 AND CHESTER A. MATHIS2 1Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 2Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania KEY WORDS positron emission tomography (PET); serotonin receptor; 5-HT2A; imaging ABSTRACT The role of serotonin in CNS function and in many neuropsychiatric diseases (e.g., schizophrenia, affective disorders, degenerative dementias) support the development of a reliable measure of serotonin receptor binding in vivo in human subjects. To this end, the regional distribution and intrasubject test–retest variability of the binding of [18F]altanserin were measured as important steps in the further development of [18F]altanserin as a radiotracer for positron emission tomography (PET) 18 studies of the serotonin 5-HT2A receptor. Two high specific activity [ F]altanserin PET studies were performed in normal control subjects (n ϭ 8) on two separate days (2–16 days apart). Regional specific binding was assessed by distribution volume (DV), estimates that were derived using a conventional four compartment (4C) model, and the Logan graphical analysis method. For both analysis methods, levels of [18F]altanserin binding were highest in cortical areas, lower in the striatum and thalamus, and lowest in the cerebellum.
  • The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    The Inhaled Steroid Ciclesonide Blocks SARS-Cov-2 RNA Replication by Targeting Viral

    bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting viral 2 replication-transcription complex in culture cells 3 4 Shutoku Matsuyamaa#, Miyuki Kawasea, Naganori Naoa, Kazuya Shiratoa, Makoto Ujikeb, Wataru 5 Kamitanic, Masayuki Shimojimad, and Shuetsu Fukushid 6 7 aDepartment of Virology III, National Institute of Infectious Diseases, Tokyo, Japan 8 bFaculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan 9 cDepartment of Infectious Diseases and Host Defense, Gunma University Graduate School of 10 Medicine, Gunma, Japan 11 dDepartment of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 12 13 Running Head: Ciclesonide blocks SARS-CoV-2 replication 14 15 #Address correspondence to Shutoku Matsuyama, [email protected] 16 17 Word count: Abstract 149, Text 3,016 bioRxiv preprint doi: https://doi.org/10.1101/2020.08.22.258459; this version posted August 24, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 18 Abstract 19 We screened steroid compounds to obtain a drug expected to block host inflammatory responses and 20 MERS-CoV replication. Ciclesonide, an inhaled corticosteroid, suppressed replication of MERS-CoV 21 and other coronaviruses, including SARS-CoV-2, the cause of COVID-19, in cultured cells. The 22 effective concentration (EC90) of ciclesonide for SARS-CoV-2 in differentiated human bronchial 23 tracheal epithelial cells was 0.55 μM.
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al

    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
  • Design and Evaluation of 5•²-O-Dicarboxylic And

    Design and Evaluation of 5•²-O-Dicarboxylic And

    University of Rhode Island DigitalCommons@URI Open Access Master's Theses 2014 DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES Bhanu Priya Pemmaraju Venkata University of Rhode Island, [email protected] Follow this and additional works at: https://digitalcommons.uri.edu/theses Recommended Citation Pemmaraju Venkata, Bhanu Priya, "DESIGN AND EVALUATION OF 5′-O-DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES" (2014). Open Access Master's Theses. Paper 474. https://digitalcommons.uri.edu/theses/474 This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information, please contact [email protected]. DESIGN AND EVALUATION OF 5′-O- DICARBOXYLIC AND POLYARGININE FATTY ACYL DERIVATIVES OF ANTI-HIV NUCLEOSIDES BY BHANU PRIYA, PEMMARAJU VENKATA A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE MASTER’S DEGREE IN BIOMEDICAL AND PHARMACEUTICAL SCIENCES UNIVERSITY OF RHODE ISLAND 2014 MASTER OF SCIENCE THESIS OF BHANU PRIYA, PEMMARAJU VENKATA APPROVED: Thesis Committee: Major Professor Keykavous Parang Roberta King Stephen Kogut Geoffrey D. Bothun Nasser H. Zawia DEAN OF THE GRADUATE SCHOOL UNIVERSITY OF RHODE ISLAND 2014 ABSTRACT 2′,3′-Dideoxynucleoside (ddNs) analogs are the most widely used anti-HIV drugs in the market. Even though these drugs display very potent activities, they have a number of limitations when are used as therapeutic agents. The primary problem associated with ddNs is significant toxicity, such as neuropathy and bone marrow suppression.